Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BIOMED LUBLIN Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 56,70 | -2,00 % | Novonesis (Novozymes A/S): Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe | Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe
A new report reveals that biosolutions could generate EUR 133 billion in economic gains and... ► Artikel lesen | |
GENMAB | 194,00 | -0,74 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
ARBUTUS BIOPHARMA | 2,954 | +2,07 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin | - New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company... ► Artikel lesen | |
VERICEL | 31,800 | -11,17 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 7,410 | +3,64 % | Sensei Biotherapeutics präsentiert Daten zu Krebstherapie auf dem ESMO-Kongress 2025 | ||
MUSTGROW BIOLOGICS | 0,448 | +2,52 % | MustGrow Biologics Corp.: MustGrow Announces Non-Brokered LIFE Offering of up to $3 Million, Proposed Repricing of Warrants, and Shares for Debt Settlement Offer to Debentureholders | Saskatoon, Saskatchewan--(Newsfile Corp. - July 30, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the following: (i)... ► Artikel lesen | |
BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | Mizuho slashes BioXcel Therapeutics stock price target to $2 from $16 | ||
REGENXBIO | 7,700 | +0,65 % | REGENXBIO Inc. (RGNX): A Bull Case Theory | ||
AKEBIA | 3,282 | +2,56 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
FENNEC PHARMACEUTICALS | 7,200 | -0,69 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
ZEVRA THERAPEUTICS | 9,250 | -3,65 % | Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C | CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
CORVUS PHARMACEUTICALS | 3,750 | -2,09 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 | ||
CARTESIAN THERAPEUTICS | 10,700 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |